Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28772770 | 0.88 | TLR7 (0.57) | TLR7NUDT1 | |
| SCHEMBL19539457 | 0.88 | TLR7 (0.57) | TLR7NUDT1 | |
| SCHEMBL2058830 | 0.88 | TLR7 (0.57) | TLR7NUDT1 | |
| SCHEMBL21449093 | 0.87 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL4128956 | 0.87 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL4134546 | 0.86 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL7211538 | 0.86 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL12726879 | 0.86 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL510344 | 0.86 | TLR7 (0.74) | TLR7NUDT1 | |
| SCHEMBL22533653 | 0.85 | TLR7 (0.61) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359360-B2 | TLR agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359360-B2 | TLR agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359360-B2 | TLR agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-07 | — | — | US | disclosed |
| EP-1931352-B1 | TLR AGONISTS | UNIV CALIFORNIA (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2510946-B1 | Conjugates of synthetic tlr agonists and uses therefor | UNIV CALIFORNIA (US) | 2015-08-05 | — | — | EP | disclosed |
| US-9050376-B2 | Conjugates of synthetic TLR agonists and uses therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050376-B2 | Conjugates of synthetic TLR agonists and uses therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050376-B2 | Conjugates of synthetic TLR agonists and uses therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140302120-A1 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-09 | — | — | US | disclosed |
| US-20140302120-A1 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-09 | — | — | US | disclosed |
| EP-2125007-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | Regents of the University of California (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1931352-A2 | TLR AGONISTS | The Regents of the University of California Office of Technology Transfer (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140302120-A1 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | TLR1, TLR5, TLR8 | TLR7 4/4885NUDT1 2757/4885 |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | TLR7 396/4885NUDT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.